Feed aggregator

Merck Ends Phase III Anti-TIGIT, Keytruda Skin Cancer Study with High Dropouts

Biospace news - Mon, 05/13/2024 - 02:00
Merck Ends Phase III Anti-TIGIT, Keytruda Skin Cancer Study with High Dropouts 5/13/2024

Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy

Biospace news - Mon, 05/13/2024 - 02:00
Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy 5/13/2024

BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs

Biospace news - Mon, 05/13/2024 - 02:00
BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs 5/13/2024

Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy?

Biospace news - Mon, 05/13/2024 - 02:00
Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy? 5/13/2024

Opinion: Travere’s Filspari Could Lead IgA Nephropathy Market

Biospace news - Mon, 05/13/2024 - 02:00
Opinion: Travere’s Filspari Could Lead IgA Nephropathy Market 5/13/2024

FDA Action Alert: Dynavax, Ascendis and BMS

Biospace news - Mon, 05/13/2024 - 02:00
FDA Action Alert: Dynavax, Ascendis and BMS 5/13/2024

Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study

Biospace news - Mon, 05/13/2024 - 02:00
Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study 5/13/2024

Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials

Biospace news - Mon, 05/13/2024 - 02:00
Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials 5/13/2024

Scientists pinpoint new vaccine "booster" that promotes potent anti-tumour immunity

World Pharma News - Fri, 05/10/2024 - 10:00
Scientists from Trinity College Dublin have made an important breakthrough that offers promise for developing new immune therapies for cancer. They have discovered that a vaccine adjuvant - or "booster" - called C100 promotes potent anti-tumour immunity when it is injected directly into tumours in an animal model.

The scientists found that C100, derived from chitin - one of the most common building materials in nature, and which gives strength to the exoskeletons of crustaceans, insects, and the cell walls of fungi - is highly effective at stimulating a key sensing and signalling molecule which regulates anti-tumour immune responses.

New treatment could reverse hair loss caused by an autoimmune skin disease

World Pharma News - Thu, 05/09/2024 - 10:00
Researchers at MIT, Brigham and Women's Hospital, and Harvard Medical School have developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss and affects people of all ages, including children.

For most patients with this type of hair loss, there is no effective treatment. The team developed a microneedle patch that can be painlessly applied to the scalp and releases drugs that help to rebalance the immune response at the site, halting the autoimmune attack.

AI predicts tumor-killing cells with high accuracy

World Pharma News - Wed, 05/08/2024 - 10:00
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.

Combined with additional algorithms, the predictive model, described in the current issue of the journal Nature Biotechnology, can be applied to personalized cancer treatments that tailor therapy to the unique cellular makeup of each patient's tumors.

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline

World Pharma News - Tue, 05/07/2024 - 10:00
Novartis announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient need.

The transaction bolsters the Novartis RLT pipeline and expands the company's research infrastructure and clinical supply capabilities, supporting Novartis strategic priorities in oncology and RLT platform innovation.

Participants of pioneering CRISPR gene editing trial see vision improve

World Pharma News - Mon, 05/06/2024 - 10:00
About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published today in the New England Journal of Medicine.

"This trial shows CRISPR gene editing has exciting potential to treat inherited retinal degeneration," said Mark Pennesi, M.D., Ph.D., a corresponding author on the paper, an ophthalmologist and Oregon Health & Science University's lead scientist for the Phase 1/2 BRILLIANCE trial.

Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expa...

Biospace news - Mon, 05/06/2024 - 02:00
Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expa... 6/5/2024

FDA Adcomm Votes Against Lykos’ MDMA-Assisted PTSD Therapy

Biospace news - Mon, 05/06/2024 - 02:00
FDA Adcomm Votes Against Lykos’ MDMA-Assisted PTSD Therapy 6/5/2024

Viking Builds Case for NASH Hopeful With Histological Data

Biospace news - Mon, 05/06/2024 - 02:00
Viking Builds Case for NASH Hopeful With Histological Data 6/5/2024

Lilly’s Zepbound Wins NICE Backing for Obese Patients With Very High BMI

Biospace news - Mon, 05/06/2024 - 02:00
Lilly’s Zepbound Wins NICE Backing for Obese Patients With Very High BMI 6/5/2024

Companies to Watch for Potential M&As in 2024

Biospace news - Mon, 05/06/2024 - 02:00
Companies to Watch for Potential M&As in 2024 6/5/2024

The ABCs of Biopharma This Week: ASCO, BIO and Cancer

Biospace news - Mon, 05/06/2024 - 02:00
The ABCs of Biopharma This Week: ASCO, BIO and Cancer 6/5/2024

AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer

Biospace news - Sat, 05/04/2024 - 02:00
AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer 4/5/2024